Cochrane Review Group

Hepato-Biliary

132 systematic reviews in Hepato-Biliary ask 1,521 questions. 19.9% have no studies to answer them, 57.6% rest on very low certainty evidence and 5.7% reach moderate or high certainty.

Reviews

132

Questions

1,521

current versions

No studies

19.9%

Moderate or high

5.7%

No studies 303 · 19.9%Ungraded 39 · 2.6%Very low 876 · 57.6%Low 216 · 14.2%Moderate 65 · 4.3%High 22 · 1.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Hepato-Biliary

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone All‐cause mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation vs conventional surgery Health‐related quality of life · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation vs conventional surgery Any adverse events or complications · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	1 study · 30 participants	Very low
Microwave coagulation vs conventional surgery Disease‐free survival · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	1 study · 30 participants	Very low
Microwave coagulation vs conventional surgery Failure to clear liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation vs conventional surgery Recurrence of liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation vs radiofrequency ablation All‐cause mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	RR 0.62 [0.26, 1.47]	1 study · 50 participants	Very low
Microwave coagulation vs radiofrequency ablation Time to mortality (overall survival) · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	HR 0.63 [0.23, 1.73]	1 study · 50 participants	Very low
Microwave coagulation vs radiofrequency ablation Health‐related quality of life · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation vs radiofrequency ablation Any adverse events or complications · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	RR 0.19 [0.01, 3.67]	1 study · 50 participants	Very low
Microwave coagulation vs radiofrequency ablation Disease‐free survival · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Time to mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies

Reviews 132

Interventions for hereditary haemochromatosis

Buzzetti, E, Kalafateli, M, et al. · Cochrane Database of Systematic Reviews · 2017

Hepato-Biliary

Thinnest evidence

Reviews 132

Interventions for hereditary haemochromatosis

Pharmacological interventions for primary biliary cholangitis

Management of people with intermediate‐stage hepatocellular carcinoma

Management of people with early‐ or very early‐stage hepatocellular carcinoma

Direct‐acting antivirals for chronic hepatitis C

Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis

Non‐steroid anti‐inflammatory drugs for biliary colic

Methods to decrease blood loss during liver resection: a network meta‐analysis

Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma

Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension

Dopamine agents for hepatic encephalopathy

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C

Methods of preventing bacterial sepsis and wound complications after liver transplantation

Low pressure versus standard pressure pneumoperitoneum in laparoscopic cholecystectomy

Wound infiltration with local anaesthetic agents for laparoscopic cholecystectomy

Fewer‐than‐four ports versus four ports for laparoscopic cholecystectomy

Pharmacological interventions for prevention or treatment of postoperative pain in people undergoing laparoscopic cholecystectomy

Methods of intraperitoneal local anaesthetic instillation for laparoscopic cholecystectomy

Nitazoxanide for chronic hepatitis C

Formal education of patients about to undergo laparoscopic cholecystectomy

Aminoadamantanes for chronic hepatitis C

Antibody induction versus corticosteroid induction for liver transplant recipients

Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients

Laparoscopic surgical box model training for surgical trainees with limited prior laparoscopic experience